HealthEquity (NASDAQ:HQY) Updates FY 2025 Earnings Guidance

HealthEquity (NASDAQ:HQY - Get Free Report) updated its FY 2025 earnings guidance on Thursday. The company provided earnings per share guidance of 2.790-2.960 for the period, compared to the consensus earnings per share estimate of 2.830. The company issued revenue guidance of $1.1 billion-$1.2 billion, compared to the consensus revenue estimate of $1.2 billion.

HealthEquity Price Performance

NASDAQ HQY traded down $0.81 during trading hours on Thursday, hitting $80.49. The company had a trading volume of 681,328 shares, compared to its average volume of 613,180. The company has a debt-to-equity ratio of 0.43, a quick ratio of 4.76 and a current ratio of 4.76. The firm has a market capitalization of $6.91 billion, a price-to-earnings ratio of 125.77, a PEG ratio of 1.30 and a beta of 0.53. HealthEquity has a 52 week low of $48.86 and a 52 week high of $84.49. The firm has a 50 day simple moving average of $80.78 and a 200 day simple moving average of $74.01.

HealthEquity (NASDAQ:HQY - Get Free Report) last posted its earnings results on Tuesday, March 19th. The company reported $0.50 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.42 by $0.08. The business had revenue of $262.39 million for the quarter, compared to analysts' expectations of $258.56 million. HealthEquity had a net margin of 5.57% and a return on equity of 6.91%. Equities research analysts expect that HealthEquity will post 2.11 earnings per share for the current year.

Wall Street Analyst Weigh In

HQY has been the topic of several research reports. Raymond James lifted their price target on HealthEquity from $90.00 to $95.00 and gave the company an outperform rating in a research report on Wednesday, December 13th. BTIG Research increased their price target on HealthEquity from $100.00 to $110.00 and gave the company a buy rating in a report on Wednesday, March 20th. Royal Bank of Canada boosted their price target on HealthEquity from $90.00 to $92.00 and gave the company an outperform rating in a research note on Wednesday, March 20th. Barclays increased their price objective on shares of HealthEquity from $84.00 to $104.00 and gave the stock an overweight rating in a research note on Friday, February 23rd. Finally, JPMorgan Chase & Co. upped their price target on HealthEquity from $86.00 to $108.00 and gave the stock an overweight rating in a research report on Tuesday, April 2nd. One investment analyst has rated the stock with a hold rating and eleven have assigned a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of Moderate Buy and an average target price of $96.17.

Insider Buying and Selling at HealthEquity

In other HealthEquity news, EVP Delano Ladd sold 2,499 shares of HealthEquity stock in a transaction dated Friday, February 9th. The stock was sold at an average price of $80.00, for a total value of $199,920.00. Following the transaction, the executive vice president now owns 49,996 shares in the company, valued at $3,999,680. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, EVP Delano Ladd sold 2,499 shares of the company's stock in a transaction on Friday, February 9th. The stock was sold at an average price of $80.00, for a total transaction of $199,920.00. Following the transaction, the executive vice president now directly owns 49,996 shares of the company's stock, valued at $3,999,680. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CEO Jon Kessler sold 33,765 shares of the firm's stock in a transaction on Friday, March 22nd. The stock was sold at an average price of $79.81, for a total value of $2,694,784.65. Following the completion of the sale, the chief executive officer now directly owns 126,635 shares of the company's stock, valued at approximately $10,106,739.35. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 71,322 shares of company stock valued at $5,682,895. 2.70% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On HealthEquity

Several institutional investors and hedge funds have recently made changes to their positions in the stock. BlackRock Inc. increased its holdings in HealthEquity by 4.0% in the 1st quarter. BlackRock Inc. now owns 9,423,008 shares of the company's stock worth $635,488,000 after buying an additional 358,743 shares during the period. Vanguard Group Inc. increased its stake in shares of HealthEquity by 1.2% in the fourth quarter. Vanguard Group Inc. now owns 8,619,499 shares of the company's stock worth $571,473,000 after acquiring an additional 104,084 shares during the period. Wasatch Advisors Inc. raised its holdings in shares of HealthEquity by 3.3% during the first quarter. Wasatch Advisors Inc. now owns 7,638,935 shares of the company's stock worth $515,170,000 after purchasing an additional 244,868 shares during the last quarter. State Street Corp lifted its position in HealthEquity by 2.4% during the second quarter. State Street Corp now owns 2,816,282 shares of the company's stock valued at $177,820,000 after purchasing an additional 65,809 shares during the period. Finally, JPMorgan Chase & Co. boosted its holdings in HealthEquity by 15.5% in the first quarter. JPMorgan Chase & Co. now owns 2,474,430 shares of the company's stock valued at $145,273,000 after purchasing an additional 331,735 shares during the last quarter. 99.55% of the stock is currently owned by institutional investors and hedge funds.

HealthEquity Company Profile

HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.